Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: Severe obesity in patients with macroprolactinoma

Swiss Medical Weekly

Volumn 136, Issue 15-16, 2006, Pages 254-258

  Schmid, Christoph ^a   Goede, Diane L ^a   Hauser, Renward S ^b   Brändle, Michael ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Kantonsspital St Gallen ^*

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Dopamine; Dopamine agonist; Macroprolactinoma; Obesity

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN;

ACROMEGALY; ADOLESCENT; ADULT; ARTICLE; BODY MASS; CUSHING DISEASE; DEMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHYSIS TUMOR; MAJOR CLINICAL STUDY; MALE; OBESITY; PROLACTINOMA; SURGICAL TECHNIQUE;

EID: 33646253167     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Creemers LB, Zelissen PMJ, van't Verlaat JW, Koppeschaar HPF. Prolactinoma and body weight: A retrospective study. Acta Endocrinol 1991;125:392-6.
2. Delgrange E, Donckier J, Maiter D. Hyperprolactinaemia as a reversible cause of weight gain in male patients? Clin Endocrinol 1999;50:271.
3. Kaji H, Sugimoto T, Nakaoka D, Okimura Y, Kaji H, Abe H, et al. Bone metabolism and body composition in Japanese patients with active acromegaly. Clin Endocrinol 2001;55:175-81.
4. Nieman LK. Diagnostic tests for Cushing's syndrome. Ann N Y Acad Sci 2002;970:112-8.
5. Hiramatsu R, Yoshida K, Sato T. A body measurement to evaluate the pattern of fat distribution in central obesity. A screening and monitoring technique for Cushing's syndrome. JAMA 1983;250:3174-8.
6. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocrine Reviews 2001;22:724-63.
7. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996;19:667-70.
8. Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol 1998;48:547-53.
9. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Anripsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
10. Comings DE, Gade R, MacMurray JP, Muhleman D, Peters WR. Genetic variants of the human obesity (OB) gene: association with body mass index in young women, psychiatric symptoms, and interaction with the dopamine D2 receptor (DRD2) gene. Mol Psychiatry 1996;1:325-35.
11. Southon A, Walder K, Sanigorski AM, Zimmet P, Nicholson GC, et al. The Taq IA and Ser311 Cys polymorphisms in the dopamine D2 receptor gene and obesity. Diabetes Nutr Metab 2003;16:72-6.
12. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, et al. Brain dopamine and obesity. Lancet 2001;357:354-7.
13. Kok P, Roelfsema F, Frölich M, Meinders AE, Pijl H. Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab 2004;89:4445-9.
14. Yermus R, Ezzat S. Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas? Clin Endocrinol 2002;56:562.
15. Tomlinson JW, Holden N, Hills RK, Wheatly K, Clayton RN, Bates AS, et al. and the West Midlands Prospective Hypopituitary Study Group. Association between premature mortality and hypopituitarism. Lancet 2001;357:425-31.
16. Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002;147:77-84.
17. Schutz Y and Woringer V. Obesity in Switzerland: a critical assessment of prevalence in children and adults. Int J of Obesity 2002;26(Suppl.2):S3-S11.
18. Beer-Borst S, Morabia A, Hercberg S, Vitek O, Bernstein MS, Glalan P, et al. Obesity and other health determinants across Europe: the EURALIM Project. J Epidemiol Community Health 2000;54:253-62.